Ozempic-maker accuses rival of false advertising
Novo Nordisk, maker of Wegovy and Ozempic, launched legal action accusing its rival Eli Lilly of false advertising on Tuesday in the US. The Danish company claims Eli Lilly, which makes Mounjaro and Zepbound, deployed ad campaigns to "create the misleading impression that Eli Lilly's medicines are superior." Novo Nordisk stated its competitor compared the highest approved doses of its medicines for obesity and type-2 diabetes with lower doses of Novo Nordisk's, while omitting newer, higher-dose options.
Eli Lilly responded to the claims, stating it stood "firmly behind our advertising." A spokesperson for Eli Lilly said their advertising is "truthful, it is transparent, and it is grounded in the most direct scientific evidence available - exactly what patients deserve." Novo Nordisk claimed Eli Lilly committed "multiple violations" of federal and state false advertising and unfair competition laws through its nationwide ad campaigns. The lawsuit comes as analysts have estimated the weight-loss drug industry could be worth more than $100 billion by 2030.
Quick Summary
Novo Nordisk has initiated legal action against Eli Lilly, accusing its rival of false advertising regarding the efficacy of their respective
Summary - read the full story for complete context.
Image: MyJoyOnline
GhanaFront aggregates news from trusted sources. Click to read the original article.
Keywords
Explore related tagsMore from MyJoyOnline
Related Stories
More from Health
GMTF Administrator hails Mintah Akandoh's support as Fund marks first year
Discover how Health Minister Kwabena Mintah Akandoh's guidance and commitment proved invaluable to the Ghana Medical Trust Fund during its critical
2d ago•
